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Badant process controlling cell deletion during post-lactational mammary gland
remodeling. The members of the Bcl-2 protein family, whose expression levels are under the control of
lactogenic hormones, internally control this mechanism. Epidermal growth factor (EGF) belongs to a family of
proteins that act as survival factors for mammary epithelial cells upon binding to speciﬁc membrane tyrosine
kinase receptors. Expression of EGF peaks during lactation and dramatically decreases in the involuting
mammary gland. Though it was suggested that the protective effect of EGF is mediated through the
phosphatidylinositol-3-kinase (PI3K) or MEK/ERK kinases activities, little is known about the downstream
mechanisms involved on the anti-apoptotic effect of EGF onmammary epithelial cells; particularly the identity
of target genes controlling apoptosis. Here, we focused on the effect of EGF on the survival of mammary
epithelial cells. We particularly aimed at the characterization of the signaling pathways that were triggered by
this growth factor, impinge upon expression of Bcl-2 family members and therefore have an impact on the
regulation of cell survival. We demonstrate that EGF provokes the induction of the anti-apoptotic isoform Bcl-
XL and the phosphorylation and down-regulation of the pro-apoptotic protein Bad. The activation of JNK and
PI3K/AKT signaling pathways promotes the induction of Bcl-XL while AKT activation also leads to Bad
phosphorylation and down-regulation. This protective effect of EGF correlatesmainlywith the up-regulation of
Bcl-XL thanwith the down-regulation of Bad. In fact, HC11 cells unable to express bcl-X, die even in the presence
of EGF. In this context, Bcl-XL emerges as a key anti-apoptotic molecule critical for mediating EGF cell survival.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionApoptosis is a tightly regulated and highly efﬁcient process. It
occurs throughout the development and growth of the mammary
gland, as was described by several authors. The most dramatic
changes due to programmed cell death occur during post-lactational
involution, when the glandular secretory tissue of the lactating
mammary gland is remodeled [1–3]. Particularly, it has been reported
that 72 h involuting glands show reduced size, lowmilk content, and a
restructured tissue organization with high amounts of dead cells and
the presence of immune inﬁltrates.
Apoptosis can be triggered by diverse stimuli that ignite signals
converging into a common cell death machinery. This process is
controlled at several intracellular check points. One of these is mainly
regulated by different members of the Bcl-2 family, which can play
opposite functions on programmed cell death. This family of proteins
is deﬁned by the presence of up to four conserved motifs known as
Bcl-2 homology domains (BH1–BH4). In addition to Bcl-2, a number ofológica, Universidad de Buenos
2.
l rights reserved.other proteins like Bcl-XL, Bcl-w and Mcl1, have an anti-apoptotic
effect. On the other hand, themembers of the pro-apoptotic group can
be divided into two subgroups: the Bax-subfamily consistingmainly of
Bax and Bak, which contain domains BH1, BH2 and BH3 and the
members of the BH3-only subfamily, which possess only the BH3
motif, like Bad, Bid, Bim, etc. [4].
Mammary gland tissue expresses a number of different Bcl-2
relatives including Bcl-X (the most abundant), Bax, Bak, Bad, Bcl-w,
Bﬂ-1 and Bcl-2 [5,6]. These proteins play a critical role in the control of
apoptosis in the mammary epithelium and their expression levels are
under the control of lactogenic hormones. While Bcl-2 is expressed in
the nonpregnant and early pregnancymammary gland, the expression
of Bax remains high during pregnancy, is down-regulated during
lactation, and is again up-regulated at the start of involution [5]. In this
sense, stimulation of bcl-2 expression and suppression of bax, were
suggested as key events in the anti-apoptotic action of prolactin in
mammary epithelial cells [7,8]. On the other hand, Bak, Bad, Bcl-w, and
Bﬂ-1 are also up-regulated during involution [5].
The activity of some members of the Bcl-2 family may also be
regulated by phosphorylation. In particular, phosphorylation of Bad on
residues Ser-112, Ser-136, Ser-155 and Ser-170 promotes its binding to
14-3-3 proteins, and its subsequent cytosolic sequestration. Importantly,
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the mitochondrial outer membrane, leaving these proteins free to exert
their anti-apoptotic function [9]. Innormalhumanbreast cells, Bad levels
are relatively high relative to other organs [10], suggesting that Bad
might have a special role in this mammary gland.
Epidermal growth factor (EGF) belongs to a family of growth factors
that interact with speciﬁc membrane receptors with tyrosine kinase
activity, Erb1 among them (reviewed in [11]). Expression of EGF is low
in themammarygland fromvirgin andpregnant animals, but increases
dramatically towards the end of pregnancy, peaks during lactation and
signiﬁcantly decreases in the involuting mammary gland [12,13]).
According to several lines of evidence it was suggested that members of
the EGF family are survival factors for mammary epithelial cells [14–16].
In this sense, it was demonstrated that mammary tumor cell lines
established from mice over-expressing the c-myc oncogene, undergo
apoptosis if cultured in the absence of EGF [15,16]. This protective effect
of EGF is blocked when the cells are grown in the presence of speciﬁc
inhibitors of EGF-receptor tyrosine kinase activity, the phosphatidyli-
nositol-3-kinase (PI3K) or MEK/ERK kinases [15–17].
HC11 ismousemammary epithelial cell line, broadly used as amodel
for studying mammary cell differentiation and apoptosis. These cells
express several members of the tyrosine-kinase receptor family.
Particularly, the dimerization and tyrosine-phosphorylation of ErbB2
and EGFR (Erb1) in EGF-stimulated HC11 cells was previously demon-
strated [18]. EGF induces proliferation in this cell line and protects the
cells from apoptosis if cultured in serum free medium (SFM) [14]. The
mechanismswherebyEGF inﬂuencesapoptosis on this cell typehavenot
been clariﬁed yet, although different options have been suggested [19].
Several studies have also addressed the relevance of the AKT
pathway in mediating cell survival [20]. Activation of AKT has been
found to block apoptosis induced by growth factor withdrawal and
loss of anchorage. Targets for AKT phosphorylation implicated in
determining cell survival, have also been identiﬁed in different
systems [21,22]. AKT can block caspase-9 activation [23], induce the
sequestration of the transcription factor Forkhead, involved in
regulating Fas ligand expression [24] and phosphorylate the pro-
apoptotic protein Bad leading to its deactivation [25]. As for mammary
gland, AKT activity peaks during pregnancy and lactation, and
decreases signiﬁcantly during mammary involution [20]. Although
AKT activation by growth factors or lactogenic hormones has been
well documented, only a few speciﬁc apoptotic targets have been
identiﬁed in mammary epithelial cells. It was reported that constitu-
tive activation of the PI3K/AKT pathway suppresses the transcriptional
up-regulation of the BH3-only protein Bmf during anoikis [26].
Besides, several reports suggest AKT dependence for the phosphor-
ylation of Bad, i.e. the apoptotic effect of TGF-β in bovine mammary
epithelial cells results in a decrease in AKT activity that correlates with
a decline in the levels of phosphorylated Bad [27].
The role of the JNK pathway in controlling cell death or survival in
the mammary gland is still controversial. In this sense, Faraldo et al.
demonstrated that a low level or absence of proliferation and an
induction ofMEC apoptosis in involuting glands correlates with lack of
JNK activation [28]. On the contrary, Small et al. reported that the over-
expression of the MAPK phosphatase 1 (MPK-1) decreased activation
of JNK and this effect correlates with apoptosis decrease in human
mammary epithelial and breast carcinoma cells [29].
Here, we analyzed the mechanisms involved on the effect of EGF
upon expression of Bcl-2 familymembers in HC11mammary epithelial
cells. We demonstrated that the addition of EGF provokes both, the
induction of the anti-apoptotic isoform Bcl-XL and the phosphoryla-
tion and down-regulation of the pro-apoptotic protein Bad; while Bcl-
2 and Bax protein levels remain unchanged. The analysis of the signal
transduction pathways involved in this effect showed that despite the
fact that ERK1/2, JNK and PI3K/AKT kinases are activated upon EGF
addition; only JNK and PI3K/AKT activities seem to be sufﬁcient to
mediate the EGF dependent inhibition of cell death. In fact, activationof PI3K/AKT by EGF correlateswith an increase in Bcl-XL and a decrease
in Badwhile JNK seems toparticipate in the control of programmed cell
death by inducing Bcl-XL. HC11 cells transfected with siRNA against
bcl-X were unable to survive in response to EGF.
In this way, our results together support the idea that while EGF
triggers a variety of responses upon the Bcl-2 family of proteins in
HC11 cells, induction of Bcl-XL emerges as a key event in mediating
EGF dependent cell survival.
2. Materials and methods
2.1. Reagents
Recombinant Human EGF was purchased from Invitrogen (Cat. No.
13247-051, Carlsbad, CA, USA). PD98059, SP600125, LY294002, H89
and MG132 inhibitors were purchased from Calbiochem (San Diego,
CA, USA). For in vitro assays 1000× solutions were prepared. Stock
solutions of kinase inhibitors were prepared in dimethyl sulfoxide.
RPMI 1640 medium and Fetal Bovine Serum (FBS) were purchased
from Invitrogen (Carlsbad, CA, USA).
2.2. Cell cultures and treatments
HC11 cells, derived from BALB/c mouse normal mammary glands
(gently provided by Dr. Nancy Hynes, Friedrich Meischer Institute,
Basel, Switzerland) were grown in RPMI 1640 growth medium (GM)
supplemented with 10% FBS containing insulin (5 μg/ml) (Sigma
Aldrich, St. Louis, MO, USA), penicillin (100 IU/ml) (Invitrogen,
Carlsbad, CA, USA) and streptomycin (100 μg/ml) (Invitrogen,
Carlsbad, CA, USA). Serum-free medium (SFM) was prepared with
RPMI 1640 medium supplemented only with penicillin (100 IU/ml)
and streptomycin (100 μg/ml). Cells were maintained at 37 °C in a
humidiﬁed atmosphere with 5% CO2.
2.3. Induction of apoptosis by serum withdrawal
Cells were trypsinized and plated in p100 plates in the conditions
described above. When the cultures reached conﬂuence, the medium
was removed; the cells were washed oncewith PBS andmaintained in
SFM during 1–2 h for starvation. After this period either SFM
containing EGF (100 ng/ml) in the presence or absence of different
kinase inhibitors PD 98059 (20 μM); SP 600125 (50 μM); LY 294002
(10 or 50 μM) or H89 (10 μM) was added. The cells were then
incubated for the time course described on each experiment.
2.4. Crystal violet staining
The number of cells still attached to the culture plate at the end of
each treatment was evaluated by crystal violet staining. HC11 cells
were plated in 96-multiwell plates and cultured until conﬂuence as
described above. Apoptosis was induced by replacing GM with SFM
and cells were maintained under these conditions during 96 h. Then,
cells were ﬁxed with 100 μl ice-cold glutaraldehyde (1.1% in PBS) for
15min at 4 °C. Sampleswerewashed three times by submersion in de-
ionized water, air-dried, and stained for 20 min with 100 μl of crystal
violet 0.1% in 200 mM phosphoric acid, pH=6. After careful aspiration
of the crystal violet, extensive washing with de-ionized water
eliminated the excess dye. Samples were then air-dried and treated
with 100 μl of acetic acid 10% during 30 min at room temperature.
Optical density was measured at 590 nm with a multiplate spectro-
photometer (Benchmark, Bio-Rad, Hercules, CA, USA).
2.5. DNA fragmentation
DNA from apoptosis induced conﬂuent HC11 cells was isolated
according to the method described by Herrmann et al. [30]. Brieﬂy,
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conﬂuence and then switched to SFM as described above. After 48 h
cells were gently resuspended in 0.1 ml lysis buffer (50 mm Tris, pH
7.5, 20 mm EDTA, and 1% Nonidet P-40) for 1 min. After centrifugation
at 4000 ×g for 5 min at room temperature the supernatant (containing
the fragmented DNA) was collected in another tube. The pellet
(nuclear DNA) was then resuspended in 0.1 ml lysis buffer. Both
fractions were incubated at 56 °C for 2 h in the presence of 5 μg/μl
ribonuclease A and 1% SDS. After ribonuclease A treatment, 5 μg/μl
proteinase K was added to each sample and further incubated at 37 °C
overnight. DNA was precipitated by the addition of 75 μl of 10 M
ammonium acetate and 450 μl absolute ethanol. After precipitation,
DNA was resuspended in 20 μl distillated water, electrophoresed in
1.5% agarose gels, and visualized under UV light.
2.6. Caspase-3-like activity assay
Caspase-3-like activity was measured. In brief, HC11 cells were
plated in p60 plates, incubated in GM at 37 °C until conﬂuence and
then switched to SFM as described above. After 4 h, treated cells were
lysed in 50 mM Tris–HCl buffer pH 7.4 containing 1 mM EDTA, 10 mM
EGTA, 10 μM digitonin, 0.5 mM PMSF, 1.54 μM aprotinin, 14.58 μM
pepstatin and 63.86 μM benzamidine, for 30 min at 37 °C. Cell lysates
were clariﬁed by centrifugation and 150 μl of the resultant super-
natant (100–200 μg protein) was incubated with 146 μl of incubation
buffer (100 mM HEPES pH 7.5, 20% glycerol, 0.5 mM EDTA and 5 mM
dithiothreitol (DTT)) and 4 μl of the substrate acetyl-Asp-Glu-Val-Asp-
7-amino-4 p-nitroanilide (Ac-DEVDpNA) (100 μM) at 37 °C for
different times (4 and 12 h). Blanks were also run, containing either
the substrate or the cell lysate alone, to deduce in each case. Caspase-
catalyzed release of the chromophore pNA from the substrate was
measured at 405 nm with a multiplate spectrophotometer (Bench-
mark, Bio-Rad, Hercules, CA, USA) and the cleavage activity was
expressed as pNA absorbance units/mg protein. Protein concentration
was determined by the method of Bradford [31] using bovine serum
albumin as a standard.
2.7. Isolation of mitochondrial and cytosolic fractions
8 h starved conﬂuent HC11 cells were lysed inMSHE buffer (0.22M
mannitol, 0.07 M sucrose, 0.5 mM EGTA, 2 mM HEPES/KOH, 1 mM
phenylmethylsulfonylﬂuoride (PMSF), 5 μg/ml leupeptin, 5 μg/ml
pepstatin, 5 μg/ml aprotinin, pH 7.4). The homogenatewas centrifuged
10 min at 1000 ×g (pellet=crude nuclear extract) followed by 20 min
at 10,000 ×g (pellet=mitochondria, supernatant=cytosol). Mitochon-
drial fractions were resuspended in MSHE buffer. The purity of both,
mitochondrial and cytosolic fractions was assessed by western blot
with antibodies against complex I and β-tubulin, respectively. Protein
content was determined by the Bradford method.
2.8. RNA analysis
Cells were resuspended in denaturing solution (4 M guanidinium
thiocyanate, 25 mM sodium citrate, pH 7; 0.1 M β-mercaptoethanol
and 0.5% sarcosyl) and total RNA was extracted by the single step
method [32]. RNase protection analysis was performed as described
previously [33]. For preparing the bcl-X probe, plasmid pGLD3 was
digested with Hinf I and transcribed by T3 RNA polymerase. The full-
length transcript size of the bcl-X riboprobe was 294 nucleotides, and
the protected fragment for bcl-XL was 237-bp long. The gapdh
template pTRIGAPDH (Ambion, Austin, TX, USA) was digested with
BglII and transcribed with T3 RNA polymerase. The probe length was
359 nucleotides, and the size of the protected fragment was 316 bp.
[α-32P]CTP (GE Health Care, Piscataway, NJ, USA) radiolabeled RNA
probes were prepared using a kit according to the instructions of the
manufacturer (Promega, Madison, WI, USA). The probes werecoprecipitated with RNA samples and dissolved in hybridization
buffer, denatured at 95 °C for 10 min, and hybridized at 52 °C for 18 h.
After digestion with RNases A and T1 followed by digestion with
proteinase K, the samples were precipitated, denatured, and subjected
to electrophoresis on a 5% denaturing acrylamide gel. Quantiﬁcation
was performed with ImageJ 1.34s software (Wayne Rasband, National
Institutes of Health, USA. http://rsb.info.nih.gov/ij/). In all of the cases,
the quantitation was normalized against gapdh signal.
2.9. Protein analysis
Total proteins were extracted from HC11 cells in RIPA protein
extraction buffer (50 mM Tris–HCl, 150 mM NaCl, 1% triton, 0.25%
sodium deoxycholate, 1 mM EDTA pH 7.4) supplemented with
protease (Protease inhibitor cocktail set I, Calbiochem, San Diego,
CA, USA) and phosphatase inhibitors (1 mM NaF, 1 mM Na2VO4). The
lysate was centrifuged at 14,300 ×g and 4 °C for 10 min, and the pellet
discarded. Cleared lysates were combined with SDS sample buffer
(50 mM Tris pH 6.8, 1% SDS, 0.1% bromphenol blue, 10% glycerol,
100 mM DTT). For western blot samples were boiled for 5 min and
electrophoresed for 3 h at 100 V in 15% or a 12%, SDS-polyacrylamide
gel, transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA) by
electroblotting in transfer buffer containing 20% methanol (vol/vol),
0.19 M glycine, 0.025 M Tris-base (pH 8.3) at 300 mA for 1.5 h at 0 °C.
Blots were blocked 1 h at room temperature in TBS (20mMTris–Cl, pH
7.5, 500 mM NaCl) containing low-fat powered milk (5%) and Tween
20 (0.1%). The incubations with primary antibodies were performed at
4 °C for 12 h in blocking buffer (3% skim milk, 0.1% Tween, in Tris-
buffered saline). The membranes were then incubated with the
corresponding counter-antibody and the proteins evidenced by
enhanced chemiluminescence detection (ECL+Plus System, GE Health
Care, Little Chalfont, Buckinghamshire, UK). As primary antibodies the
followingwere used:α-Bcl-XL/S (sc-634);α-Bax (sc-493);α-Bcl-2 (sc-492);
α-P-ERK1/2 (sc-7383); α-ERK1/2 (sc-154); α-P-JNK (sc-6254); α-JNK
(sc-474-G); α-P-p38 (sc-7973); α-p38 (sc-535-G); α-AKT (sc-1618); α-
cytochrome c (sc-13156); α-ubiquitin (sc-8017); α-tubulin (sc-9104)
andα-actin (sc-1616-R) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and α-P(Ser112)-Bad (#9296); α-P(Ser136)-Bad (#9295); α-Bad
(#9292) and α-P-AKT (Cell Signaling Technology, Beverly, MA, USA)
and α-Complex I NDUFA9 (421344) (Molecular Probes Inc., Eugene, OR,
USA). As secondary antibodies the following were used: a peroxidase-
labeled α-rabbit IgG; α-mouse IgM or α-goat IgG (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) orα-mouse IgG (Bio-Rad, Hercules,
CA, USA). Densitometric analysis of protein levels was performed with
ImageJ 1.34s software (Wayne Rasband, National Institutes of Health,
USA. http://rsb.info.nih.gov/ij/).
2.10. siRNA synthesis and transfection
Desalted DNA oligonucleotides were purchased at Invitrogen
(Carlsbad, CA, USA). (i) T7, 5′-TAATACGACTCACTATA G-3′. (ii) Bcl-X;
sense, 5′-AAATATCCTTTCTGGGAAAGCTATAGTGAGTCGTATT A-3′;
antisense, 5′-AAGCTTTCCCAGAAAGGATACTATAGTAGGTCGTATTA-3′.
Control of inespeciﬁc sequence; sense, 5′-AAAATTTAGCGCAGCAT-
TACCTATAG TGAGTCGTATTA-3′; antisense, 5′-AAGGTAATGCTGCGC-
TAAATCTATAGTGA GTCGTATTA-3′. The oligonucleotide-directed
production of small RNA transcripts with T7 RNA polymerase has
been described [34]. For each transcription reaction, 1 nmol of each
oligonucleotidewas annealed in 50 μl of TE buffer (10mM Tris–HCl pH
8.0, and 1mMEDTA) by heating at 95 °C; after 2min, the heating block
was switched off and allowed to cool down slowly to obtain dsDNA.
Transcription was performed in 50 μl of transcription mix: 1× T7
transcription buffer (40 mM Tris–HCl pH 7.9, 6 mMMgCl2, 10 mMDTT,
10 mM NaCl and 2 mM spermidine), 1 mM rNTPs, 0.1 U yeast
pyrophosphatase (Sigma Aldrich, St. Louis, MO, USA), 40 U RNAsin
(Promega, Madison, WI, USA) and 100 U T7 RNA Polymerase
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template. After incubation at 37 °C for 2 h, 1 U RNAse free-DNAse
(Promega, Madison,WI, USA) was added at 37 °C for 15min. Sense and
antisense RNAs generated in separate reactions were annealed by
mixing both crude transcription reactions, heating at 95 °C for 5 min
followed by 1 h at 37 °C to obtain ‘T7 RNA polymerase synthesized
small interfering double stranded RNA’ (T7 siRNA). The mixture
(100 μl) was then adjusted to 0.2 M sodium acetate pH 5.2, and
precipitated with 2.5 vol ethanol. After centrifugation, the pellet was
washed once with 70% ethanol, dried, and resuspended in 50 μl of
RNAse free water.
For liposome-mediated siRNAs transfection HC11 cells were
seeded into 6-well plates 24 h prior to treatment. Transfection of T7
siRNAs was carried out with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) as directed by the manufacturer for adherent cell
lines. 0.5 or 2 μl of T7 siRNAs were applied per well. Cells were
harvested and lysed 48 h later for Bcl-XL protein level analysis. For cell
survival experiments cells were switch to GM or keep in SFM for 48 h
after siRNA transfection and the number of cells still attached to the
culture plate was evaluated by crystal violet staining as described
above adjusting the volumes to 6-well plates.
2.11. Statistical analysis
Results were expressed as means±standard error or means±standard
deviation, as it is indicated in the ﬁgure legends. For Bcl-XLFig. 1. EGF reverts apoptosis induced by cell density and SFM in HC11 cells by a mechanism th
on SFM and then stimulated with EGF (100 ng/ml) from 5 min to 4 h. Equal amounts of pr
antibodies against (A) phosphorylated ERK1/2 and total ERK1/2 (ﬁrst set, upper panels), phos
set, lower panels) and phosphorylated AKT (second set, upper panels) and total AKT (secon
Conﬂuent HC11 cells were kept on SFM with the addition of EGF (100 ng/ml) and/or kinase in
was assessed by crystal violet staining assays performed after 96 h treatment and is expre
replicates from three independent experiments (n=15). ⁎=pb0.05. (C) Agarose gel electrop
representative of three independent experiments. (D) Caspase-3 activity was determined up
activity was calculated as A405/mg protein under the standard incubation conditions and ex
experiments are shown. ⁎=pb0.05. (E) Cytochrome C release was tested by western blots per
blots against Complex I NDUFA9 protein and β-tubulin were performed to conﬁrm the efﬁ
quantitated. The bars indicate the ratio between the band corresponding to the mitochond
representative of three independent experiments.studies, ANOVA followed by Student–Newman–Keuls post hoc test
was used to determine statistically signiﬁcant differences (pb0.05).
For crystal violet staining and caspase-3-like activity, one-way
ANOVAs followed by Tukey's multiple comparisons tests were used
to detect signiﬁcant differences among treatments. Statistical
analyses were performed with STATISTICA 6.0 (StatSoft, Inc.).
Differences were regarded as signiﬁcant at pb0.05. Before
statistical analysis data were tested for normality and homosce-
dasticity using Lilliefors and Bartlett's tests, respectively.
3. Results
3.1. EGF inhibits apoptosis through the activation of JNK and PI3K
The EGF dependent activation proﬁles of the protein kinases ERK1/
2, JNK, p38 MAPK and AKT was analyzed by Western blot of the
phosphorylated forms on extracts obtained from HC11 conﬂuent cells
treated with EGF for 5 min to 4 h on SFM. Fig. 1A shows that EGF
induces a transient increase in the phosphorylation levels of ERK1/2
and JNK between 5 and 15 min after its addition (lanes 3 to 5, ﬁrst and
third panels, respectively). The activity of both enzymes was not
affected by the absence of serum (compare lanes 1 and 2). On the
other hand, p38 kinase presents a relatively high basal level of
phosphorylation, which is a consequence of the absence of serum in
the culture (ﬁfth panel, lane 2); however, the phosphorylation degree
of p38 is not modiﬁed by the addition of the growth factor (ﬁfth panel,at involves JNK and PI3K kinase pathways. Conﬂuent HC11 cells were starved during 1 h
otein from each sample were analyzed by western blot. Membranes were probed with
phorylated JNK and total JNK (middle panels), phosphorylated p-38 and total p-38 (ﬁrst
d set, lower panels). Results are representative of three independent experiments. (B)
hibitors as indicated: PD98059 (20 μM), SP600125 (50 μM), LY294002 (50 μM). Viability
ssed as percentage of the internal control (with FBS). Bars indicate Mean±S.E. of ﬁve
horesis of a DNA ladder from conﬂuent HC11 cells treated as in (B) for 48 h. The gel is
on 4 h of treatment by measuring the proteolysis of Ac-DEVDpNA during 12 h. Speciﬁc
pressed as fold induction against the control. The means±S.E. from three independent
formed on mitochondrial and cytosolic fractions of HC11 cells treated as in (C). Western
ciency of fraction recovery. Bands corresponding to Cytochrome c were scanned and
rial fraction and the band from the cytoplasmic fraction for each treatment. The gel is
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between 5 to 10 min – (Fig. 1A, lower set).
After 96 h in SFM the number of viable cells fell down to 55.6±4.6%.
However, cell viability was restored to 82.5±2.7% in the presence of
EGF (100 ng/ml) (Fig. 1B, lane 3). To test the involvement of the
different kinase pathways in this protective effect we used speciﬁc
kinase inhibitors for MEK/ERK1/2 (PD 98059, PD); JNK (SP 600125, SP)
and PI3K/AKT (LY 294002, LY). Results show that only SP and LY
blocked EGFmediated protection (Fig.1B, columns 7 and 9) and that in
SFM, both kinase inhibitors, SP and LY, decreased cell viability per se
(columns 6 and 8). These results suggest a putative role for both, JNK
and PI3K/AKT pathways on EGF-induced cell survival. Conversely,
MEK/ERK1/2 speciﬁc inhibitor PD (columns4 and5), althougheffective
in blocking ERK1/2 phosphorylation (insert to the right in Fig. 1B) is
unable to affect EGF-mediated cell survival (81.8±4.3%) or the SFM-
induced cell viability (48.4±3.9%).
To analyze whether the protection conferred by EGF on HC11 cell
viability is related to inhibition of apoptosis, we performed DNAFig. 2. EGF increases Bcl-XL expression by JNK and PI3K kinase pathways and down-regulates
EGF (100 ng/ml) for 5 and 8 h. Cell lysates were analyzed by western blot. Membranes wer
(middle lower panel) and Bad (lower panel) proteins. Representative gels from three indepe
induction relative to the controls. The means±S.E. from three independent experiments are
from conﬂuent HC11 cells starved during 1 h on SFM and then stimulated with EGF (100 ng/m
as a negative control and medium with FBS as a positive control. A representative gel out of
fold induction is shown in the column graph at the bottom. Themeans±S.E. from three indep
pre-incubated with kinase inhibitors as indicated and then EGF (100 ng/ml) was added for 5
against Bcl-X and actin proteins as indicated. Representative gels from three independent ex
relative to the control. The means±S.E. from three independent experiments is shown (bar g
cells pre-incubated with PD98059 (20 μM), SP600125 (50 μM) and LY294002 (10 or 50 μM) f
The protected bands of long bcl-X isoform and gapdh are shown. tRNA is used as a negative co
Values were normalized to gapdh. The means±S.E. from three independent experiments arfragmentation assays. HC11 conﬂuent cells were incubated in SFM
with or without EGF plus the kinase inhibitors PD, SP and LY. Fig. 1C
shows that after 48 h, a laddering of DNA was detected in cells
incubated on SFM alone (lanes 1 and 5) that considerably decreased
by addition of EGF (lanes 2 and 6). This protective effect was still
present when cells were incubated with PD but not observed in the
presence of the kinase inhibitors, SP and LY (lanes 3, 4 and 7
respectively).
We next observed that EGF inhibits the activation of caspase 3
provoked by serum depletion (Fig. 1D, columns 2 and 3). While this
EGF effect was blocked by all the kinase inhibitors tested, PD
(column 4), SP (column 5) and LY (columns 6 and 7), the caspase 3
activity turned out signiﬁcantly high in the presence of these two
last inhibitors which indicates a per se effect of these drugs.
Taken together, these results suggest that even though three
kinase pathways are activated upon EGF addition, only JNK and PI3K/
AKT signaling are relevant on the EGF-dependent cell death
protection.Bad. (A) Conﬂuent HC11 cells were starved during 1 h on SFM and then stimulated with
e probed with antibodies against Bcl-X (upper panel), Bcl-2 (middle upper panel), Bax
ndent experiments are shown. Bcl-XL and Bad protein expression are expressed as fold
shown (A, column graph). ⁎=pb0.05. (B) RNAse protection assay of total RNA harvested
l) for 2, 3, and 5 h. The protected fragments of bcl-XL and gapdh are shown. tRNA is used
three independent experiments is shown. Values were normalized to gapdh and bcl-XL
endent experiments are shown. ⁎=pb0.05. nt, nucleotides. (C) Conﬂuent HC11 cells were
h. Cell lysates were analyzed by western blot. Membranes were probed with antibodies
periments are shown. Bcl-XL levels normalized to actin are expressed as fold induction
raph). ⁎=pb0.05. (D) RNase protection assay of total RNA harvested from conﬂuent HC11
or 1 h in SFM as indicated and then treated with EGF(100 ng/ml) for 3 h is being shown.
ntrol. A representative gel out of three independent experiments is shown (lower panel).
e shown for bcl-XL fold induction (upper panel). ⁎=pb0.05. nt, nucleotides.
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Western blot analysis using an antibody against Cytochrome C
was performed upon extracts of mitochondrial and cytosolic
fractions of HC11 lysates. Effective fractionation was tested using
antibodies against the Complex 1 protein NDUFA9 and β-tubulin,
(Fig. 1E). The ratio of protein present in mitochondria compared to
cytosol was calculated (columns in the upper panel) after
quantiﬁcation of the western blots developed with anti-CytC
antibodies. We observed that incubation in SFM resulted in a
dramatic release of Cytochrome C from the mitochondria as shown
by a reduction of this ratio, which is restored to normal levels by
the addition of EGF.
3.3. EGF increases Bcl-XL and down-regulates Bad expression
Western blot assays were performed in order to analyze the
expression levels of themembers of the Bcl-2 family in HC11 conﬂuent
cells treated with EGF in SFM for 5 or 8 h. Results shown in Fig. 2A
indicate that HC11 cells treated with EGF exhibit signiﬁcantly higher
protein levels of Bcl-XL as compared with cells incubated in SFM alone
(1.6±0.2 and 1.9±0.2 fold induction for 5 and 8 h, respectively) (ﬁrst
panel lanes 2 and 4). On the opposite way, Bad levels decrease upon
EGF addition (0.76 and 0.36 fold induction for 5 and 8 h, respectively)
(fourth panel lanes 2 and 4). Neither Bcl-2 nor Bax proteins change
their levels upon EGF addition on HC11 conﬂuent cells (Fig. 2A, second
and third panels, respectively).Fig. 3. Bad protein is phosphorylated at Ser112 and Ser136 and down-regulated after EGF tr
cells were starved during 1 h on SFM and then stimulated with EGF (100 ng/ml) for 5 to 30
Ser112, phosphoBad-Ser136, total Bad and actin. Levels of p-Bad/Bad from one representati
relative to the control. (B) and (C) Conﬂuent HC11 cells were pre-incubated with kinase inhibi
Cell lysates were analyzed by western blot. Membranes were probed with antibodies again
levels of p-Bad/Bad from one representative out of three independent experiments are sh
inhibitor as indicated and then stimulated with EGF (100 ng/ml) for 20 min. Cell lysates wer
actin and ubiquitin as indicated. Relative levels of Bad from three independent experimentsEGF-mediated bcl-XL up-regulation was also observed in RNAse
protection assays performed in HC11 cells treated with EGF (Fig. 2B).
Serumwithdrawal results in a considerable decrease in the messenger
level of the bcl-XL isoform (lane 3). This effect is reverted upon EGF
addition, that restores and increases bcl-XL levels to 1.76±0.26 fold
after 3 h of treatment (Fig. 2B, lane 6). We conclude that EGF increases
both themessenger and protein levels of bcl-XL in HC11 conﬂuent cells
in a way compatible with its anti-apoptotic effect suggesting that up-
regulation of Bcl-XL would play a key role in EGF-mediated cell
survival.
In order to study the participation of different kinase pathways on
the effect of EGF on bcl-XL, we treated HC11 conﬂuent cells with EGF in
SFM during 5 h in the presence of the different pharmacological
inhibitors. Fig. 2C shows that the increase in Bcl-XL protein levels
triggered by EGF is completely blocked when cells are co-incubated
with SP or LY but not with PD. The analysis of bcl-X transcripts shows
that while LY diminishes bcl-XL messenger levels in a dose-dependent
manner, the JNK inhibitor does not affect EGF mediated increase in
bcl-XL mRNA (Fig. 2D).
3.4. EGF induces phosphorylation of Bad
Inactivation of Bad involves its phosphorylation [9]. We analyzed
whether there is a correlation between the phosphorylation degree of
Bad and the decrease on its expression levels. Fig. 3A depicts a time
course of both, Bad phosphorylation degree and protein levels in
conﬂuent HC11 cells treated in SFM with or without EGF. The increaseeatment independently of the 26S proteasome degradation system. (A) Conﬂuent HC11
min. Cell lysates were analyzed by western blot with antibodies against: phosphoBad-
ve out of three independent experiments are shown and represented as fold induction
tors as indicated and then stimulated with EGF (100 ng/ml) for 5min (B) and 20min (C).
st phosphoBad-Ser112, phosphoBad-Ser136, total Bad and actin as indicated. Relative
own. (D) Conﬂuent HC11 cells were pre-incubated for 20 h with MG132 proteasome
e analyzed by western blot. Membranes were probed with antibodies against total Bad,
are shown.
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addition in both residues, Ser-112 and Ser-136, previously described as
targets of ERK1/2 or PKA respectively. In addition, EGF induces a
decrease in total Bad protein levels upon 10 min of treatment,
reaching a minimum after 20 min of incubation (lanes 3 to 6). Thus,
our results show a steady increase in the ratio of phosphoBad/Bad at
both target residues (bar graphics).
In order to identify the kinase pathway/s mediating EGF-
dependent Bad phosphorylation, we made use of the set of kinase
inhibitors. Fig. 3B shows that LY blocks Ser-136 without affecting Ser-
112 phosphorylation (upper set, lane 3) while PD inhibits Ser-112
phosphorylation (lower set, lane 6). Both inhibitors are also able to
block the EGF-mediated decrease in Bad levels after 20 min of
incubation (Fig. 3C, lanes 3 and 6, respectively). On the other hand,
though SP partially inhibited the EGF dependent Bad Ser-112
phosphorylation (Fig. 3B lower set, lane 7) it was not able to restore
Bad down-regulation (Fig. 3C, lane 7).
According to a recent report, Bad phosphorylation may affect this
protein's stability by ubiquitylation and proteasomal degradation [35].
In order to test this possible mechanism, we performed experiments
in the presence of a proteasome inhibitor, MG132. Fig. 3D shows that
the decrease in Bad levels is still observed in conﬂuent HC11 cells
treated with EGF (Fig. 3D, lane 2) despite MG132's ability to
accumulate ubiquitylated proteins (Fig. 3D, right panel). These results
suggest that, in our conditions, the down-regulation of Bad is
independent of the 26S proteasome degradation system.
3.5. Putative role of Bcl-XL in EGF-dependent cell survival
Together the results show that the protective effect of EGF
correlates mainly with the up-regulation of the anti-apoptotic protein
Bcl-XL rather than the down-regulation of Bad, as the inhibition of JNK
by SP blocks both, Bcl-XL up-regulation and cell survival without
preventing Bad decrease. To test the role of Bcl-XL as amediator in EGFFig. 4. Bcl-XL is involved on EGF-dependent cell survival. (A) and (B) HC11 cells were seeded i
for (A) and 200 pmol for (B)] and control (200 pmol) were transfected. Cells were harvested
actin. Relative levels of Bcl-XL normalized to actin from three independent experiments a
transfected with 200 pmol of siRNAs as indicated. Cells were switched to GM or kept in SFM
Results are expressed as percentage of the internal control (control siRNA without EGF). Badependent cell survival we performed small interfering RNA (siRNA)
assays. Fig. 4A shows the effect on bcl-X expression upon increasing
amounts of the speciﬁc siRNA. In fact, the addition of 50 pmol of siRNA
is enough to down-regulate the expression of Bcl-XL around 50%. The
speciﬁcity of the effect is validated treating cells with an unspeciﬁc
siRNA (Fig. 4B). Then we analyzed the effect of EGF on cell survival in
the presence of bcl-X and control siRNAs. We performed two
approaches: 1) under apoptotic conditions (cells cultured on SFM)
(Fig. 4C, left panel) and 2) on survival conditions (cells cultured on
GM) (Fig. 4C, right panel). After 48 h in SFM the number of viable cells
fell down to 47±3.6% and could not be recovered by the presence of
EGF (100 ng/ml) when the cells were incubated with bcl-X siRNA
(Fig. 4C, left panel). However, bcl-X siRNA was unable to decrease
the cell viability upon cells grown on complete media (with FBS)
(Fig. 4C, right panel). Together these results suggest the relevance of
Bcl-XL in mediating EGF survival in an apoptotic context.
4. Discussion
Many cellular processes are modulated by phosphorylation/
dephosphorylation of molecular components, activating cascades of
protein kinases upon determined stimuli. Among factors promoting
growth and proliferation in mammary cells, EGF exerts its action by
interacting with EGFR, a member of the ErbB receptor family. This
interaction promotes cell survival and is involved in all the major
mechanisms controlling cell death (reviewed in [36]). In this sense,
survival factors such as Ras, PI3K/AKT, and Bcl-XL/-2 are activated by
ErbB signaling in several systems [36]. However, the mechanism by
which this family of proteins prevents apoptosis has not been
completely elucidated. As for mammary epithelial cells it has been
demonstrated that EGF, IGF-I, and basic ﬁbroblast growth factor
(bFGF) act as survival factors [13]. In fact, excess activation of signaling
downstream of ErbB1, has been linked to the development of breast
cancer and to chemotherapeutic resistance [37].nto 6-well plates 24 h prior to treatment and siRNAs against bclx [50 pmol and 200 pmol
48 h later and lysates were analyzed by western blot with antibodies against: Bcl-X and
re shown. (C) HC11 cells were seeded into 6-well plates 24 h prior to treatment and
for 48 h after transfection and viability was assessed by crystal violet staining assays.
rs indicate Mean±S.E. of two replicates from three independent experiments (n=6).
Fig. 5. Complex dynamic signaling mediates EGF-dependent cell survival. PI3K/AKT and
JNK signaling pathways activated by EGF lead to up-regulation of Bcl-XL. PI3K/AKT and
ERK1/2 activation also leads to Bad phosphorylation on Serine136 and Serine112
respectively and Bad protein down-regulation. The cell protective effect of EGF
correlates mainly with the up-regulation of the anti-apoptotic protein Bcl-XL as noted
by the thick lines.
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EGF prevents apoptosis in HC11 cells by activating different signal
transduction pathways. Our results showed that EGF treatment results
in the activation of MEK/ERK, PI3K and JNK pathways. The involve-
ment of p38 kinase activity in the mechanism of action of EGF was
ruled out as our results showed high levels of phosphorylated p38 in
cells cultured in SFM regardless of the presence of EGF. Noteworthy, an
EGF-dependent activation of p38 kinase in HC11 cells has been
recently reported [19]. This discrepancy could be attributed to a
difference in cell culture conditions as we observed an increase in the
phosphorylation degree of p38 when the cells were incubated during
1 h on SFM; while in the other report authors evaluated the effect of
EGF in differentiated HC11 cells cultured in 10% FBS [19].
Our results show ERK1/2 is activated by EGF, but this signaling
pathway would not be relevant in mediating its activity as a promoter
of cell survival in our system. This is supported by the fact that while
the ERK1/2 inhibitor prevents EGF-dependent inhibition of caspase-3
and Bad down-regulation, it does not affect the cell survival rate
obtained in the presence of the growth factor. In this sense, Galbaugh
et al. have suggested that the Ras/Mek/ERK pathway is mainly
preventing the EGF-dependent repression of speciﬁc target genes
involved in differentiation [19].
On the other hand, we demonstrate that both PI3K/AKT and JNK
pathways are crucial inmediating the inhibition of apoptosis by EGF as
their activation is involved in controlling the expression levels and
phosphorylation degree of some members of the Bcl-2 family. The
protective effect of EGF in HC11 cells includes an increase in the levels
of the anti-apoptotic protein Bcl-XL and the phosphorylation and
down-regulation of the pro-apoptotic protein Bad, but no changes in
Bcl-2 or Bax protein levels. Similar results were reported by Merlo et
al., who showed that the sharp increase observed in Bax protein levels
with increased cell density is independent of the presence of EGF.
These authors havementioned that Bcl-2 is slightly up-regulated upon
EGF addition in conﬂuent human MCF-10 cells [38].
According to our results EGF increases Bcl-XL expression in two
different ways, at least: 1) by increasing bcl-XL transcripts levels
through the activation of PI3K and; 2) through a mechanismmediated
by both JNK and PI3K resulting in a rise in its protein levels. Thus, it is
tempting to speculate that up-regulation of Bcl-XL plays a key role in
the survival of HC11 cells mediated by EGF.
A variety of soluble growth factors inhibit apoptosis by phosphor-
ylation of Bad on multiple serine residues [9,39,40]. Activation of
receptors that regulate PI3K result in phosphorylation of Bad on Ser-
136 [41], whereas activation of the MAPK pathway phosphorylates
Bad on ser-112 and Ser-155 [42]. Phosphorylation in these three
residues promotes Bad inactivation by sequestration in the cytoplasm
that prevents interaction with Bcl-XL [9,39,43].
Upon EGF addition, Bad is phosphorylated by ERK1/2 in Ser-112
and by PI3K/AKT in Ser-136. Ser-112 can also be phosphorylated by
PKA; however this would not be the case for EGF-dependent (Ser-
112)-Bad phosphorylation as it was not inhibited by the PKA inhibitor,
H89 (data not shown). Our results suggest that the activation of both
kinase pathways ERK1/2 and PI3K are necessary for EGF dependent
Bad phosphorylation and down-regulation. However, the ERK1/2
pathway is not involved in the regulation of cell viability by EGF.
Phosphorylation of Bad by AKT increases its interaction with 14-3-
3 proteins and prevents the dimerization of Bad with Bcl-XL,
promoting cell survival [9,39,43]. An opposite effect of JNK-dependent
phosphorylation of Bad at Ser-128 has been recently described in
neurons [44]. In these cells, JNK-dependent phosphorylation of Bad
inhibits the interaction of phosphoBad-(Ser-136) with 14-3-3 pro-
teins, thereby promoting the apoptotic effect of Bad [44]. The
activation of the JNK pathway plays a critical role in naturally
occurring apoptosis during development as well as in pathological
death associated with different diseases. Under most circumstances in
non-malignant cells, JNK activation results in turn in the activation ofpro-apoptotic members of Bcl-2 family and in cytochrome C release
from mitochondria (reviewed in [45]). However, JNKs have also been
implicated in enhancing cell survival and proliferation. In this sense, it
has been reported that JNK can suppress apoptosis in IL-3-dependent
hematopoietic cells via phosphorylation of Bad [46]. This kinase
pathway seems to represent an archetype of contrariety in intracel-
lular signaling [47].
Our results show that EGF-dependent activation of the PI3K/AKT
pathway induces an increase in phosphoBad-(Ser-136) levels and a
concomitant down-regulation of Bad protein. We also found that EGF
decreases Bad levels even in the presence of the JNK inhibitor,
supporting the notion that this effect is independent of Ser-128
phosphorylation.
The question arising from these results is: “What is the role of Bad
phosphorylation in the protective effect of EGF?” as it does not seem to
be sufﬁcient in the prevention of apoptosis. Complete activation of the
mitochondrial-tethered portion of glucokinase would require Bad
phosphorylation at Ser-136 and Ser-155. One possibility is suggested
by this recently reported metabolic function of Bad, that is
independent of its pro-apoptotic activity [48].
Together our results describe a complex dynamic pattern by which
EGF modulates cell survival (Fig. 5). Two signaling pathways activated
by EGF promote the induction of Bcl-XL while AKTactivation also leads
to Bad phosphorylation and down-regulation. However, the protective
effect of EGF correlates mainly with the up-regulation of the anti-
apoptotic protein Bcl-XL.
Walton et al. [49] demonstrated that the deletion of the bcl-X gene
from the entire mammary epithelial compartment (ducts and alveoli)
did not compromise proliferation or differentiation of mammary
ductal and alveolar epithelial cells in virgin mice and during
pregnancy and lactation; however, epithelial cell death and tissue
remodeling is accelerated in the bcl-X conditional knockout mice
during the ﬁrst stage of involution. Moreover, the ratio between the
anti-apoptotic bcl-XL isoform and the pro-apoptotic bcl-XS, signiﬁ-
cantly decrease in involuting glands of wild-typemice [50], suggesting
that Bcl-X is not essential during mammopoiesis but is critical for
controlling apoptosis during involution. The fact that EGF circulating
levels also decrease in involuting glands reveals a putative critical role
for bcl-X as mediator in the EGF dependent epithelial cell survival. In
this sense, siRNA assays performed against bcl-X support this
hypothesis, as the EGF protective effect disappears in bcl-X deleted
cells.
Thus, Bcl-XL emerges as a key anti-apoptotic molecule critical for
mammary oncogenesis and tumor progression. In fact, it was
demonstrated that Bcl-XL expression correlates with a decrease in
cellular sensitivity toward a variety of chemotherapeutic reagents
providing high cell resistance against them. According with these and
504 L. Romorini et al. / Biochimica et Biophysica Acta 1793 (2009) 496–505our previous results [51], Bcl-XL plays a key role as mediator in cell
survival induced by such different stimuli as growth factors and
glucocorticoids, both strong inhibitors of apoptosis in mammary
epithelium. In this sense, the conditional deletion of the bcl-X gene
from mouse mammary epithelium results in accelerated apoptosis
during the ﬁrst stage of involution. This phenotype is no further
modiﬁed by the deletion of Bax protein [49]. In view of the new goals
of clinical research, detailed studies of the mechanisms, signaling
pathways and speciﬁc target genes involved in the regulation of cell
survival in mammary epithelial cells will provide information that
may be clinically relevant and inﬂuence therapeutic decisions for the
development and use of new drugs.
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